Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group

This publication has 19 references indexed in Scilit:

• Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial
  Journal of Clinical Oncology, 2003
• Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
  Journal of Clinical Oncology, 2002
• Survival among U.S. Women with Invasive Epithelial Ovarian Cancer
  Gynecologic Oncology, 2002
• Phase II Trial of Oral Altretamine for Consolidation of Clinical Complete Remission in Women with Stage III Epithelial Ovarian Cancer: A Southwest Oncology Group Trial (SWOG-9326)
  Gynecologic Oncology, 2001
• Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results
  JNCI Journal of the National Cancer Institute, 2000
• Second-Line Treatment of Ovarian Cancer
  The Oncologist, 2000
• Altretamine (Hexamethylmelamine) in Platinum-Resistant and Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Phase II Trial
  Gynecologic Oncology, 1998
• Hexamethylmelamine as a Single Second-Line Agent in Ovarian Cancer: Follow-up Report and Review of the Literature
  Gynecologic Oncology, 1997
• Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
  New England Journal of Medicine, 1996
• Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer
  Gynecologic Oncology, 1992